Effect of TNF-α inhibition on urinary albumin excretion in experimental diabetic rats
- 1 September 2007
- journal article
- Published by Springer Science and Business Media LLC in Acta Diabetologica
- Vol. 44 (4), 215-218
- https://doi.org/10.1007/s00592-007-0007-6
Abstract
The objective is to assess the effect of TNF-α inhibition on urinary albumin excretion in experimental diabetic rats. Male Wistar rats, 8-week-old, were categorized into four groups, which were the control ( n = 9), diabetes ( n = 9), infliximab-treated diabetes ( n = 10), and FR167653-treated diabetes ( n = 9) groups. Diabetes was induced by intraperitoneal injection of STZ (40 mg/kg). Thereafter, infliximab was injected intraperitoneally once a month (5.5 mg/kg) and FR167653 was administered orally by mixing with the rat chow (0.08%). The effects of infliximab and FR167653 on urinary albumin excretion were observed for 12 weeks. Body weight, blood sugar, 24-h urinary TNF-α, and 24-h urinary albumin/creatinine ratio (Ualb/Ucr) levels were determined at 1, 4, 8, and 12 weeks after the STZ-injection. Treatment of rats with STZ caused a significant loss of body weight, as well as polyuria and hyperglycemia within 1 week, while the urinary excretions of albumin and TNF-α were increased. Neither infliximab nor FR167653 affected body weight or blood sugar levels, whereas both decreased urinary albumin excretion, together with a modest decrease in the urinary excretion of TNF-α. These results suggest a role of TNF-α in the pathogenesis of diabetic nephropathy and show that TNF-α inhibition is a potential therapeutic strategy.Keywords
This publication has 17 references indexed in Scilit:
- Tumor necrosis factor-α gene expression in diabetic nephropathy: Relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibitionKidney International, 2005
- Urinary and renal interstitial concentrations of TNF-α increase prior to the rise in albuminuria in diabetic ratsKidney International, 2003
- Elevated levels of interleukin-18 and tumor necrosis factor-α in serum of patients with type 2 diabetes mellitus: Relationship with diabetic nephropathyMetabolism, 2003
- Usefulness of a Highly Sensitive Urinary and Serum IL-6 Assay in Patients with Diabetic NephropathyNephron, 2000
- Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: Effects of pentoxifylline administrationAmerican Journal of Kidney Diseases, 1999
- Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitisGastroenterology, 1999
- Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor ? monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritisArthritis & Rheumatism, 1998
- FR167653, a dual inhibitor of interleukin-1 and tumor necrosis factor-α, ameliorates endotoxin-induced shockEuropean Journal of Pharmacology, 1997
- Effect of FR167653, a cytokine suppressive agent, on endotoxin-induced disseminated intravascular coagulationEuropean Journal of Pharmacology, 1996
- Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathyKidney International, 1991